International AIDS Society iasociety.org

Access to long-acting pre-exposure prophylaxis (PrEP)

Perspectives from the Medicines Patent Pool

Sébastien Morin (MPP, Switzerland)
19 October 2026 – Lilongwe, Malawi

Conflict of Interest Disclosure

- I have no relevant financial relationships with pharmaceutical companies or other conflict of interest to disclose.

Thanks to the entire MPP team!



Acknowledgments

- The work of the Medicines Patent Pool in HIV is made possible by the financial support of Unitaid.
- We thank them, as well as our other current public and philanthropic funders.

Existing PrEP options

Oral PrEP (TDF/XTC)



365 pills/year

Dapivirine vaginal ring



12 rings/year

Injectable LA-PrEP options

Cabotegravir



6 injections/year
(7 during first year)

Lenacapavir



2 doubles injections/year
(3 during first year)

Adapted from Lobna Gaayeb @ AFRAVIH 2026

Emerging injectable LA-PrEP options
Originator product registration to date

Both are registered in Malawi

CAB as PrEP
(ViiV Healthcare)

1 National submissions

65 National approvals

31 Regulatory authorities approvals



LEN as PrEP
(Gilead Sciences)

8 National submissions

51 National approvals

19 Regulatory authorities approvals



More at: https://www.lapal.ch/landscape/regulatory-status

Emerging LA-PrEP options
Voluntary licences enabling future access to generics

In the development pipeline

	Cabotegravir (2-monthly injectable)	**Lenacapavir** (6-monthly injectable)	**Alimatravir** (monthly oral)
Originator	**ViiV Healthcare**	**Gilead Sciences**	**MSD**
Licence	• **Covers at least 133 countries** (including countries without patents for CAB)	• **Covers 120 countries**	• **Covers at least 129 countries** (including countries without patents for alimatravir)
Licensed generics	**3 generic manufacturers** • Aurobindo • Cipla • Viatris	**6 generic manufacturers** • Dr. Reddy's • Emcure • Eva Pharma • Ferozsons Laboratories • Hetero • Viatris	**7 generic manufacturers** • Aspen • Aurobindo • Cipla • Emcure • Quality Chemical Industries • Universal Corporation • Viatris

More at: https://www.medspal.org

Emerging LA-PrEP options
Countries able to access future generic versions



More at: https://www.medspal.org

Malaysia: Access to generic CAB will be possible following patent expiry in October 2027. Source: https://www.medspal.org

Emerging LA-PrEP options
Current & future prices



Alimatravir could be mass produced for <5 USD per person per year

RESEARCH LETTERS

Check for updates

The estimated cost of MK-8527 produced at scale for once-monthly oral HIV pre-exposure prophylaxis in low- and middle-income countries

Samuel Cross[a], Jacob Levi[b], Francois Venter[c], Andrew Hill[d]

Authors and Affiliations >

AIDS 40(8):p 1209-1212, August 2026. | *DOI:* 10.1097/QAD.0000000000004487

Source: https://www.prepwatch.org/long-acting-status-update (December 2025) & https://doi.org/10.1097/qad.0000000000004487

In summary

The tools needed for effective HIV prevention exist & continue to evolve



HIV prevention also requires that all PLHIV have access to optimal ART



TLD remains the preferred first-line option
WHO also differentiates its offer

1. **TAF-based treatment as alternative to TDF**
   - Daily oral TAF-ED or TAF-LD
   - Can already be accessed as generic across sub-Saharan Africa!

2. **Simplified treatment with two oral ARVs**
   - Daily oral DTG/3TC
   - Can already be accessed as generic across sub-Saharan Africa!

3. **Long-acting injectable treatment**
   - Two-monthly injectable CAB + RPV
   - Under development as generic for all of sub-Saharan Africa!

All of these represent opportunities for Malawi



Source: https://www.who.int/publications/i/item/9789240119468 & https://accesspal.org/

Some recommendations…
PrEP now, PrEP in the future, and the power of U=U

1. **Continue expanding access to PrEP** to increasing numbers of people and as a menu of options

2. **Continue supporting access to effective HIV treatment**, with TLD (and pALD) as central programmatic pillars, and newly-recommended options as needed to help individual adherence and optimize clinical outcomes

3. **Start planning for emerging PrEP and treatment options** currently at clinical and generic product development stages

1. **Oral PrEP, CAB, LEN, DVR**

2. **TLD, pALD, TAF-ED, TAF-LD, DTG/3TC**

3. **AMI** (PrEP), **CAB + RPV** (treatment)

Thanks for your attention!

Thanks to our funders!

Unitaid SAVE LIVES FASTER

Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra
Swiss Agency for Development and Cooperation SDC

MINISTÈRE DE L'EUROPE ET DES AFFAIRES ÉTRANGÈRES
Liberté Égalité Fraternité

From the People of Japan

In partnership with Canada

german cooperation DEUTSCHE ZUSAMMENARBEIT

Government of Flanders

Coefficient Giving



Sébastien Morin
Senior Manager – Policy, Strategy & Market Access
smorin@mppf.ch



Maureen Luba
Board Member (MPP)
Senior Advisor – Global Policy (AVAC)
maureenluba@gmail.com

And thanks for your collective dedication to HIV care for all

MedsPaL THE MEDICINES PATENTS AND LICENCES DATABASE

LAPaL THE LONG-ACTING THERAPEUTICS PATENTS AND LICENCES DATABASE

AccessPaL ACCESS PATHWAYS AND LIFECYCLE TRACKER